Second-line treatment paradigms for diffuse large B-cell lymphomas

Current Oncology Reports

Volumn 11, Issue 5, 2009, Pages 386-393

  Thieblemont, Catherine ^b   Gisselbrecht, Christian ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; OXALIPLATIN; PLATINUM DERIVATIVE; PREDNISONE; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVIEW; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; SALVAGE THERAPY; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 68949154549     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0052-0     Document Type: Review

References (49)

1. Pfreundschuh M, Trumper L, Kloess M, et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
2. Coiffier B, Lepage E, Briere J, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
3. Feugier P, Van Hoof A, Sebban C, et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
4. Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
5. Bosly A, Coiffier B, Gisselbrecht C, et al.: Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992, 10:1615-1623.
6. Chau I, Webb A, Cunningham D, et al.: An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001, 115:786-792.
7. Corazzelli G, Capobianco G, Arcamone M, et al.: Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009 Feb 15 (Epub ahead of print).
8. El Gnaoui T, Dupuis J, Belhadj K, et al.: Rituximab, gemcitabine and oxaliplatin: An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007, 18:1363-1368.
9. Gisselbrecht C, Glass B, Mounier N, et al.: R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study [abstract]. J Clin Oncol 2009, 27(15 Suppl):8509.
10. Kewalramani T, Zelenetz AD, Nimer SD, et al.: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004, 103:3684-3688.
11. Lopez A, Gutierrez A, Palacios A, et al.: GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: A phase II study. Eur J Haematol 2008, 80:127-132.
12. Vellenga E, van Putten WL, van't Veer MB, et al.: Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: A prospective randomized HOVON trial. Blood 2008, 111:537-543.
13. Martin A, Conde E, Arnan M, et al.: R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93:1829-1836.
14. Khouri IF, Saliba RM, Hosing C, et al.: Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005, 23:2240-2247.
15. Horwitz SM, Negrin RS, Blume KG, et al.: Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004, 103:777-783.
16. Chen L, Monti S, Juszczynski P, et al.: SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008, 111:2230-2237.
17. Friedberg J, Sharman J, Schaefer-Cutillo J, et al.: Fostamatinib disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (SLL/CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:3.
18. Robertson MJ, Kahl BS, Vose JM, et al.: Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:1741-1746.
19. Morschhauser F, Zinzani PL, Burgess M, et al.: Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2007, 48:708-715.
20. Park CM, Bruncko M, Adickes J, et al.: Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 2008, 51:6902-6915.
21. Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
22. Cilley J, Winter JN: Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas. Haematologica 2006, 91:114-120.
23. Gisselbrecht C, Bethge W, Duarte RF, et al.: Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2007, 40: 1007-1017.
24. Krishnan A, Nademanee A, Fung HC, et al.: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008, 26: 90-95.
25. Shimoni A, Zwas ST, Oksman Y, et al.: Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007, 35:534-540.
26. Chiesa C, Botta F, Di Betta E, et al.: Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: Possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biother Radiopharm 2007, 22:113-120.
27. Blay J, Gomez F, Sebban C, et al.: The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998, 92:3562-3568.
28. Guglielmi C, Gomez F, Philip T, et al.: Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998, 16:3264-3269.
29. Porrata LF, Ristow K, Habermann TM, et al.: Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2009, 84:93-97.
30. Panovska-Stavridis I, Georgievski B, Cevreska L, et al.: Rituximab plus ICE regimen for relapsed and refractory aggressive non-Hodgkin lymphoma [abstract]. Haematologica 2004, 89(Suppl 1):763.
31. Obrlikova PO, Vackova B, Pylik R, et al.: Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for diffuse large B-cell lymphoma [abstract]. Haematologica 2006, 91:217.
32. Herishanu Y, Terstman S, Perri C, et al.: The combination of rituximab, etoposide, ifosfamide, and carboplatin (RICE) is safe and effective salvage therapy for elderly patients with aggressive non-Hodgkin's lymphoma [abstract]. Haematologica 2005, 90:999.
33. Mey UJ, Olivieri A, Orlopp KS, et al.: DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: A matched-pair analysis. Leuk Lymphoma 2006, 47:2558-2566.
34. Shrestha S, Johnson C, Jain S, et al.: ESHAP +/- rituximab as salvage therapy for relapsed lymphoma prior to stem cell transplant: Single institution experience [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:4601.
35. Venugopal P, Gretory SA, Showel J, et al.: Rituximab (Rituxan) combined with ESHAP chemotherapy is highly active in relapsed/refractory aggressive non-Hodgkin's lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:4636.
36. Hicks L, Buckstein R, Mangel J, et al.: Rituximab increases response to ESHAP in relapsed, refractory, and transformed aggressive B-cell lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:3067.
37. Arnold C, Cuthbert R, Morris TCM, et al.: Rituximab-ESHAP as salvage therapy in relapsed aggressive B cell lymphoma [abstract]. Haematologica 2005, 90(Suppl 1):1146.
38. Bieker R, Kessler T, Berdel WE, Mesters RM: Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Oncol Rep 2003, 10:1915-1917.
39. Aydin S, Duhrsen U, Nuckel H: Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients. Ann Hematol 2007, 86:271-276.
40. Rupolo M, Spina M, Michieli M, et al.: R-DHAOX as salvage regimen in patients (pts) with relapsed/resistant non-Hodgkin's lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:1323.
41. Wenger C, Stern M, HerAmann R, et al.: Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leuk Lymphoma 2005, 46: 71-75.
42. Corazzelli G, Russo F, Capobianco G, et al.: Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/ mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study. Ann Oncol 2006, 17(Suppl 4):iV18-iv24.
43. Cabanillas F, Liboy I, Rodriguez-Monge E, et al.: A dose dense low toxicity salvage regimen for histologically aggressive non-Hodgkin's lymphoma (NHL): Gemcitabine, rituximab, oxaliplatin combination (GROC) plus pegfilgrastim [abstract]. J Clin Oncol 2006, 24(June 20 Suppl):17513.
44. Smith S, Toor A, Klein J, et al.: The combination of gallium nitrate, rituximab and dexamethasone is effective and safe as a salvage regimen for diffuse large B-cell lymphoma [abstract]. J Clin Oncol 2006, 24(June 20 Suppl):17510.
45. Strauss SJ, Morschhauser F, Rech J, et al.: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006, 24:3880-3886.
46. Niitsu N, Kohuri M, Higashihara M, Bessho M: Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma. Cancer Sci 2006, 97:933-937.
47. Younes A, McLaughlin P, Romaguera J, et al.: Paclitaxel plus topotecan plus rituximab (TTR): An effective salvage program for the treatment of patients with relapsed/refractory aggressive B-cell non Hodgkin's lymphoma [abstract 220]. Presented at the Ninth International Conference on Malignant Lymphoma (ICML). Lugano, Switzerland; June 8-11, 2005.
48. Canales M, Sanjurjo M, García-Vela J, et al.: Paclitaxel and topotecan in combination with rituximab as effective second-line salvage regimen in resistant aggressive non-Hodgkin's lymphoma [abstract 494]. Presented at the Ninth International Conference on Malignant Lymphoma (ICML). Lugano, Switzerland; June 8-11, 2005.
49. Woehrer S, Hejna M, Skrabs C, et al.: Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology 2005, 69:499-502.